Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19447720 | 1.00 | L3MBTL1 (0.45) | L3MBTL1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL16645333 | 1.00 | L3MBTL1 (0.45) | L3MBTL1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL13013979 | 0.92 | ALDH1A1 (0.44) | L3MBTL1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL18807566 | 0.91 | HSD17B10 (0.44) | L3MBTL1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL15468169 | 0.90 | MEN1 (0.47) | L3MBTL1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL13013975 | 0.90 | ALDH1A1 (0.47) | L3MBTL1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL19605901 | 0.90 | FOLH1 (0.45) | FOLH1MEN1KMT2ASLC6A9S1PR1 | |
| SCHEMBL10060136 | 0.90 | FOLH1 (0.45) | FOLH1MEN1KMT2ASLC6A9S1PR1 | |
| SCHEMBL13013980 | 0.88 | OPRM1 (0.40) | L3MBTL1FOLH1MEN1KMT2ALMNA | |
| SCHEMBL9032439 | 0.88 | FOLH1 (0.45) | FOLH1ALDH1A1S1PR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| EP-3222617-B1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2017197251-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3222617-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | The Johns Hopkins University (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2017-05-11 | — | — | US | disclosed |
| EP-2408755-B1 | Urea-based peptide compounds useful for detecting inter alia prostate cancer | UNIV JOHNS HOPKINS (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9056841-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | H1-3, H1-2, H1-4 | L3MBTL1 797/4885FOLH1 522/4885MEN1 529/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | L3MBTL1 3697/4885FOLH1 81/4885MEN1 2971/4885 |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | L3MBTL1 2898/4885FOLH1 1/4885MEN1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.